Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.
Multiple sclerosis (MS) is a heterogeneous inflammatory demyelinating disorder of the central nervous system (CNS). People with MS typically have a relapsing remitting disease course, with episodic neurological dysfunction corresponding to inflammation in the brain or spinal cord. Some relapsing patients develop a secondary progressive disease course, with accumulation of disability over time, yet other people with MS only experience a primary progressive course. Over the past 20 years, 14 immunomodulatory therapies have been approved in MS in order to reduce the frequency of inflammatory relapses and prevent CNS damage. Of the available types of therapies, the monoclonal antibodies are generally the most effective at dampening MS disease activity. In this review we will discuss the development of effective monoclonal antibody therapies coinciding with a better understanding of the complex immunopathogenesis of MS, both successes and failures, as well as targets for future development that address the mechanisms underlying progressive disease.
Division of Neuroimmunology and Neuroinfectious Disease, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
J L
JL
Orthmann-Murphy
Division of Neuroimmunology and Neuroinfectious Disease, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
P A
PA
Calabresi
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018450:Disease Progression; D015195:Drug Design; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors